Navigation Links
InfraReDx Announces Publication of a Case Report in Circulation Highlighting Novel Clinical Finding with LipiScan™ Coronary Imaging System
Date:12/7/2010

BURLINGTON, Mass., Dec. 7, 2010 /PRNewswire/ -- InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced the publication of a case report in Circulation describing the association of stent thrombosis with lipid core plaque as detected by its LipiScan™ Coronary Imaging System. The LipiScan is the first and only FDA-approved system to provide a Chemogram™ (map of lipid core plaque) within the imaged vessel via near-infrared (NIR) spectroscopy. The authors note that the case represents the first demonstration of acute stent thrombosis associated with disrupted lipid core plaque (LCP) as detected by NIR imaging with the LipiScan system.

The paper titled "Residual Thrombogenic Substrate After Rupture of a Lipid Rich Plaque – Possible Mechanism of Acute Stent Thrombosis? A Near-Infrared Spectroscopy Study" was published in Circulation (2010;122:2349-2350) under authors Sakhuja R., Suh W., Jaffer F. and Jang I.

"While stenting is an excellent means to treat flow restrictions caused by coronary plaques, it is in some cases complicated by thrombosis which may cause serious consequences," said James E. Muller, M.D., founder and chief executive officer of InfraReDx. "This report by Sakhuja et al. describes the occurrence of thrombosis in a stent that ends in a lipid core plaque, a structure that contains substances known to be thrombogenic. This adds to the accumulating evidence that many complications of stenting – peri-stenting infarction, stent thrombosis and restenosis – are due not to features of the stent or stenting technique, but to the presence of a lipid core plaque at the stented site. We are pleased to make available the LipiScan IVUS Coronary Imaging System, which provides an easy and accurate method to detect lipid core plaque and thereby adds important information to the decision-making process."

Since this LipiScan examination was performed, InfraReDx has received FDA clearance (see September 1, 2010 news release) for its next-generation LipiScan IVUS Coronary Imaging System, which now combines both NIR (LipiScan) and intravascular ultrasound (IVUS) technologies. The IVUS feature provides an image of the plaque and coronary artery lumen, while the NIR feature provides rapid and accurate assessment of LCPs. Upon completion of a single catheter pullback, the LipiScan IVUS system is able to immediately generate and display a grayscale IVUS image of the coronary artery, along with a complete and co-registered Chemogram within the imaged vessel.

About InfraReDx, Inc.InfraReDx, Inc. is a privately funded medical device company improving patient care through the development and commercialization of intelligent imaging technologies to improve the diagnosis and treatment of coronary artery disease. InfraReDx's LipiScan™ IVUS Coronary Imaging System is the first and only available catheter to combine both near-infrared spectroscopy (NIR) and intravascular ultrasound (IVUS) technologies to both visualize and characterize the intracoronary lipid core plaques (LCP) suspected of causing the majority of heart attacks. Founded in 1998, InfraReDx is headquartered in Burlington, Massachusetts. For more information, visit www.infraredx.com.  Contacts:Susan Heins (media)Pure Communications, Inc.864-286-9597sjheins@purecommunicationsinc.com Grant FrazierVice President of MarketingInfraReDx, Inc.781-345-9632gfrazier@infraredx.com
'/>"/>

SOURCE InfraReDx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
2. First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System
3. InfraReDx to Showcase the LipiScan(TM) Coronary Imaging System at the Cardiovascular Research Foundations (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Meeting
4. InfraReDxs LipiScan(TM) Coronary Imaging System for Identification of Lipid Core Plaque to be Highlighted at 59th Annual Scientific Session of the American College of Cardiology
5. InfraReDxs New LipiScan™ IVUS Coronary Imaging System to be Highlighted at TCT 2010
6. InfraReDx Completes $21 Million Equity Financing
7. InfraReDx Announces Presentation of LipiScan™ Research at American Heart Association Scientific Sessions 2010
8. InfraReDx to Present at Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
(Date:6/23/2016)... , June 23, 2016 Leading ... that address medical conditions resulting from a breakdown ... has appointed Greg Doyle as chief ... Leading BioSciences, executive management team and board of ... chief financial officer. He will provide continued leadership ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Alkermes PLC ... AMAG ), IDEXX Laboratories Inc. (NASDAQ: IDXX ... Learn more about these stocks by accessing their free trade ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
(Date:6/24/2016)... ... June 24, 2016 , ... To ... infrastructure. Most providers, however, are unsure how to move forward, given the need ... define a path forward tailored to an organization’s specific needs. , PYA Principal ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... SpiritQuest Sedona ... heart of West Sedona, surrounded by famous vortex sites: Cathedral Rock, Airport Mesa, and ... partner properties – the Lodge at Sedona as well as the Sedona Rouge, both ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... An ... may expose a possible link between head and neck cancer in individuals with unhealthy ... the study were evaluated based on whether they had gum disease, brushed their teeth ...
(Date:6/23/2016)... ... 23, 2016 , ... SyncDog, Inc. , the leading ... is featured in the current issue of Silicon Review magazine. Silicon ... technology solutions and features them in their magazine. The magazine allows top-level executives ...
Breaking Medicine News(10 mins):